Greenwich Lifesciences Inc (GLSI) - Total Liabilities
Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) has total liabilities worth $5.24 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Greenwich Lifesciences Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Greenwich Lifesciences Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Greenwich Lifesciences Inc to evaluate short-term liquidity relative to the company's equity base.
Greenwich Lifesciences Inc Competitors by Total Liabilities
The table below lists competitors of Greenwich Lifesciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NXG NextGen Infrastructure Income Fund
NYSE:NXG
|
USA | $54.45 Million |
|
Brainchip Holdings Ltd
AU:BRN
|
Australia | AU$3.46 Million |
|
Peoples Bancorp of North Carolina
NASDAQ:PEBK
|
USA | $1.58 Billion |
|
Flexsteel Industries Inc
NASDAQ:FLXS
|
USA | $104.87 Million |
|
Spok Holdings Inc
NASDAQ:SPOK
|
USA | $52.93 Million |
|
Arqit Quantum Inc.
NASDAQ:ARQQ
|
USA | $7.73 Million |
|
Pizza Pizza Royalty Corp.
TO:PZA
|
Canada | CA$75.61 Million |
|
RF Capital Group Inc
TO:RCG
|
Canada | CA$1.06 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Greenwich Lifesciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Greenwich Lifesciences Inc total assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Greenwich Lifesciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Greenwich Lifesciences Inc (2017–2025)
The table below shows the annual total liabilities of Greenwich Lifesciences Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.02 Million | +29.29% |
| 2024-12-31 | $1.56 Million | +429.79% |
| 2023-12-31 | $294.41K | +11.98% |
| 2022-12-31 | $262.90K | -31.74% |
| 2021-12-31 | $385.17K | -63.16% |
| 2020-12-31 | $1.05 Million | -24.08% |
| 2019-12-31 | $1.38 Million | -86.54% |
| 2018-12-31 | $10.23 Million | +19.53% |
| 2017-12-31 | $8.56 Million | -- |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Ph… Read more